DeciBio releases the 4th Edition of its Fluidigm Report---LOS ANGELES, CA (DeciBio – May 24th, 2012) - Today, DeciBio released the fourth edition of its Fluidigm report (https://www.decibio.com/2012/05/24/fluidigm-poised-for-growth/).In this 4th edition, we review the company’s past revenues, forecast revenues by platform and provide an overview of the market and competitive landscape. The report contains the following updates:

1. Forecasted Fluidigm revenues (2012-2015): For the first time, we breakdown projected installed base and revenues by system:
2. BioMark / BioMark HD for gene expression analysis and single-cell genomics and other applications (e.g., dPCR)
3. EP1 for genotyping and dPCR - Access Array for NGS sample preparation
5. C1 single-cell AutoPrep for single-cell isolation
7. Topaz for crystallography applications
8. Revamped market analysis from 2007-2015: We present the market size, segmentation, growth and trends for the two markets Fluidigm participate in:
9. Genomics tools for academic, BioPharma and applied market customers
10. Molecular diagnostics for (IVD) clinical diagnostic laboratories
11. Analysis of the competitive landscape: We provide an overview of the offerings from Fluidigm’s key competitors:
12. qPCR mid-plex players
13. dPCR players, including Life Technologies, QuantaLife (Bio-Rad), Raindance, and 4 less known players with emerging technologies
15. MDx players

Based on this information and the feedback of ~18 customers and non-customers, we provide an updated SWOT analysis.

Authors: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel